Posters

Title Date Documents

2016 Annual Report

A Phase 1/2 Multidose, Dose Escalation Study to Evaluate RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects with Advanced Neovascular AMD (NVAMD) #3210

Targeting Immune Checkpoints Using Self-Delivering RNAi (sd-rxRNA) Technology - Presented at: Cavendish Global Impact Forum

Targeting Immune Checkpoints Using Self-Delivering RNAi (sd-rxRNA®) Technology - Presented at: TIDES

Prevention of UVR Induced MMP1 Upregulation-MMP1 Targeting sd-rxRNA May Reduce the Effects of Skin Photo-aging - Presented at Society of Investigative Dermatology

Topical Application of sd-rxRNA Compounds for Reduction of Hyperpigmentation - Presented at the Society of Investigative Dermatology

Enhancement of CAR T Cell Activity via PD-1 Silencing with sd-rxRNA® Self-Delivering RNAi Compounds - Presented at: American Association for Cancer Research (AACR) Annual Meeting

RXi Q4 and Year End 2014 Earnings Conference Call Transcript

RXi Q4 and Year End 2016 Earnings Conference Call Transcript

Targeting Immune Checkpoints Using Self-Delivering RNAi (sd-rxRNA) Technology - Presented at: 2nd Annual Oligonucleotide and Peptide Therapeutics Conference